Open AccessImmunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma
Author(s) -
Ahmed O. Kaseb,
Luis M. Vence,
Jorge Blando,
Shalini S. Yadav,
Naruhiko Ikoma,
Roberto Carmagnani Pestana,
JeanNicolas Vauthey,
James P. Allison,
Padmanee Sharma
Publication year - 2019
Publication title -
cancer immunology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.976
H-Index - 87
eISSN - 2326-6074
pISSN - 2326-6066
DOI - 10.1158/2326-6066.cir-18-0605
Subject(s) - medicine , nivolumab , immunotherapy , ipilimumab , perioperative , hepatocellular carcinoma , adjuvant , oncology , clinical trial , surgery , cancer
In hepatocellular carcinoma (HCC), surgical resection is associated with high recurrence rate, and no effective adjuvant therapy currently exists. We initiated a pilot randomized trial of perioperative immunotherapy with nivolumab and ipilimumab for resectable HCC. Here, we provide an illustrative report of a case that achieved a complete response and report immunologic correlates of this complete pathologic response to perioperative immunotherapy. Clinical response was correlated with an increase in CD8 + T-cell infiltration, with an increase in two effector T-cell clusters. This study is ongoing, and the final results may contribute to a paradigm shift in the perioperative treatment of HCC, leading to the incorporation of immunotherapy in the curative setting.